We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01042379
Recruitment Status : Recruiting
First Posted : January 5, 2010
Last Update Posted : January 25, 2018
Information provided by (Responsible Party):
QuantumLeap Healthcare Collaborative

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 2020
  Study Completion Date : No date given

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):